Oslo, 17 July 2024

Reference is made to the stock exchange announcement by Observe Medical ASA
("Observe Medical" or the "Company", OSE ticker: OBSVR)) on 26 June 2024,
regarding notice of an extraordinary general meeting in connection with a
private placement and contemplated subsequent offering in the Company.

The extraordinary general meeting was held today, on 17 July 2024, at 14.00
hours (CEST). All resolutions proposed by the board of directors were approved,
including (i) the issuance of 16,862,962 offer shares to complete tranche 2 of
the private placement, (ii) granting the board of directors an authorisation to
increase the Company's share capital by up to NOK 8,450,000, in connection with
the contemplated subsequent offering, and (iii) granting the board of directors
a general authorisation to increase the Company's share capital by up to NOK
12,775,630, in order to finance further growth.

A detailed description of the subsequent offering, including the terms and
conditions, as well as factors to consider when subscribing for shares in the
subsequent offering, will be disclosed in an offer and listing prospectus to be
published before the subscription period for the subsequent offering begins. It
is expected that the subscription period for the subsequent offering will last
from 19 September 2024 at 09:00 to 3 October 2024 at 16:30, provided that the
prospectus for the subsequent offering is approved in time.

The minutes from the extraordinary general meeting are enclosed hereto and will
also be available on the Company's website www.observemedical.com/investor
-relations.

For further information, please contact:

Jørgen Mann, Interim CEO Observe Medical

Mobile: +45 408 67 558

E-mail: jorgen.mann@observemedical.com

Johan Fagerli, CFO Observe Medical

Mobile: +47 958 12 765

E-mail: johan.fagerli@observemedical.com

About Observe Medical:

Observe Medical is a Nordic medtech company that develops, markets and sells
innovative medtech products for the global market. The Company is committed to
improving patient welfare and patient outcomes, improving clinical data accuracy
and promoting positive health economics.

The Company seeks to drive growth by leveraging its expertise in sales and
commercialisation of its broad portfolio of medical technology products, mainly
in urine measurement and ultrasound, in combination with targeted M&A and
distribution. Observe Medical is working with a network of leading distributors
to provide outstanding solutions for healthcare professionals globally.

The Company is headquartered in Oslo, Norway.

Further information is available at www.observemedical.com.

This information is subject to the disclosure requirements pursuant to Section 5
-12 of the Norwegian Securities Trading Act.